The study is designed to examine the safety of CNDO-109-activated allogeneic NK cells, as well as the relapse-free survival and overall survival in adults with AML
Data from the CORRECT study showed regorafenib plus best supportive care significantly improved overall survival and progression-free survival compared to placebo plus BSC (6.4 months vs. 5 months and 1.9 months vs. 1.7 months, respectively
Genentech Inc., of South San Francisco, a member of the Roche Group, reported results from the Phase III AVAglio study showing that Avastin (bevacizumab) in combination with radiation and temozolomide chemotherapy improved progression-free survival by 36 percent vs
Median progression-free survival was 6.7 months, and overall survival was 21.5 months...The trial, PICASSO 3, is a randomized, double-blind, placebo-controlled study evaluating progression-free survival in metastatic soft-tissue sarcoma
The primary endpoint of the 33-patient study is to determine the clinical benefit rate, while secondary objectives include progression-free survival and safety and tolerability
Celgene Corp., of Summit, N.J., said its Celgene International Sarl subsidiary reported the data safety monitoring board (DSMB) determined that the Phase III study MM-003 testing pomalidomide plus low-dose dexamethasone compared to high-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma met the primary endpoint of improvement in progression-free survival (PFS) at the PFS final analysis
Secondary endpoints include safety, overall survival, complete hematologic response CR, progression-free survival, duration of response and quality of life
The single-arm, open-label study will enroll up to 20 patients, with a primary endpoint of objective response rate and secondary endpoints of safety and tolerability, duration of response, complete remission rate and progression-free survival
Pfizer Inc., of New York, said a Phase III study of Inlyta (axitinib) did not meet its primary endpoint of demonstrating statistically significantly longer progression-free survival (PFS) vs. Nexavar (sorafenib, Onyx Pharmaceuticals Inc. and Bayer AG) in treatment-naïve patients with advanced renal cell carcinoma
The secondary endpoint is progression-free survival...TH-302 previously met its endpoint of progression-free survival in a Phase II study, though investors were disappointed when overall survival data fell short of statistical significance. (See BioWorld Today, Feb. 22, 2012, and Sept. 18, 2012
Eli Lilly and Co., of Indianapolis, said the Phase III REGARD trial testing ramucirumab in patients with metastatic gastric cancer met its primary endpoint of improved overall survival and also showed prolonged progression-free survival
About 150 men will be randomized 2-to-1 to receive tasquinimod or placebo, and the primary endpoint is radiological progression-free survival...Secondary objectives include progression-free survival, evaluation of tumor response and immunological response
The primary endpoint in the second stage will be a comparison of progression-free survival, and secondary endpoints will assess response rate and overall survival
The NETTER-1 study will compare Lutathera to Sandostatin LAR (octreotide, Novartis AG) in patients and will measure progression-free survival as the primary endpoint...The study will assess overall survival and progression-free survival in patients 60 years and older
The study is designed to examine the safety of CNDO-109-activated allogeneic NK cells, as well as the relapse-free survival and overall survival in adults with AML